Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.

Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr

The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.

PIB: Pharma companies manufacturing generic medicine

Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.

PIB: Quality control of Ayush drugs